Find disease awareness content and relevant supporting materials

Major advances in the understanding of the pathophysiology of melanoma have led to a new era of melanoma treatment with targeted therapy and immunotherapies. Since 2011, four new classes of medications...

Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...

We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations.

Pembrolizumab is an approved first-line systemic therapy for unresectable metastatic melanoma. Despite the achievement of complete and durable responses in a small subgroup of patients, it is standard practice that ...

Cutaneous melanoma is the most common type of melanoma, and UV exposure is one of the main risk factors.

The SEOM-GEM guidelines address the rising incidence of cutaneous melanoma and emphasize early diagnosis and timely treatment. They provide evidence-based recommendations for adjuvant and neoadjuvant therapies, advanced disease management, and follow-up strategies, including special cases like brain metastases.

This European consensus guideline updates diagnostic recommendations for cutaneous melanoma. It covers dermoscopy, imaging, mutation testing, and stage-based follow-up strategies to improve early detection and patient outcomes.

Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma.

Detection and removal of melanoma, before it has metastasized, dramatically improves prognosis and survival.

The introduction of BRAF and MEK inhibitors into clinical practice improved the prognosis of metastatic melanoma patients. The combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown...